Agile Therapeutics, Inc. (AGRX) is focused on the fulfillment of women’s unmet health needs. It offers women contraceptive options and the preliminary product of the company is Twirla transdermal system.
AGRX stock price in the regular trading on March 11, 2022, with a decrease of 6.58% was $0.26. Its price rebounded by 7.31% at the last check of the aftermarket session.
AGRX: Events and Happenings
On March 11, 2022, AGRX reported its Executive management to present at the following investor conferences.
- Virtual Oppenheimer’s 32ndAnnual Healthcare Conference was held on March 17, and
- Virtual Maxim Group and M-Vest 2022 Growth Conference held on March 28, 2022.
On March 07, 2022, AGRX announced to issue its fourth-quarter 2021 financials on March 30, 2022. On January 12, 2022, AGRX acknowledged the issuance of guidelines by the tri-agencies, Department of Labor, Health and Human Services, and Treasury to aid in women’s accessibility to FDA-approved contraceptives. On January 10, 2022, AGRX informed the press about its collaboration with Afaxys Pharma, for the promotion of the Twirla transdermal system.
AGRX: Key Financials
On November 2, 2021, AGRX released its consolidated third-quarter 2021 financial report for the period ended September 30, 2021. Some important aspects are mentioned below.
Revenue
Net revenue delivered by the company in Q3 2021 was $1.3 million compared to no revenue in the same period of 2020. The company reported a 100% surge in its YoY net revenue. Also, it missed the revenue target by $175.2 thousand.
EPS
Net loss basic and diluted per share for the company during Q3 2021 was $16.8 million or $0.18 against $15.5 million or $0.18 in the same quarter of 2020. The company topped the EPS estimates by $0.01 and its net loss inclined YoY.
Conclusion
AGRX stock is down-performing as it hit 50% year-to-date as the pandemic-related economic restrictions are going to ease internationally. The company announced the upcoming presentation of its Executive management at the virtual investor’s conferences, resultantly its stock swelled. Also, the company is estimating $1.51 million revenue for Q4 2021 against -$0.15 EPS.
